Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. - Wikidata - awgldk - TriplyDB

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

http://www.wikidata.org/entity/Q33388660

about

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy Oncolytic viruses: From bench to bedside with a focus on safety.Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Oncolytic immunotherapy: where are we clinically?Chapter two--Adenovirus strategies for tissue-specific targeting.Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Increasing the efficacy of oncolytic adenovirus vectors Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia Serotype chimeric human adenoviruses for cancer gene therapy.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.Oncolytic adenovirus based on serotype 3.Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.Treatment of chemotherapy-refractory cancer in the advanced therapy access program.Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.

P2860

Q27001601-5E0222DE-DDFB-4404-A3F6-2E5891C819D6 Q33700352-14C2EDE9-829F-4FD5-AA6D-C90A03E284D8 Q34044071-6A8E28A0-846D-4D21-A222-0264B0F3366B Q34178183-4BB7779D-975E-4396-B503-3E9B69856488 Q34405325-6CA4018B-ADA8-40D3-AEC7-E23E37916C98 Q34643252-2ACCC59B-1C75-4DCE-8425-B7066B2C2E47 Q35224606-FBED4729-AFED-4CF3-AE97-867821777C75 Q35238258-8589243D-5504-4D54-B19A-C5051D3BCE13 Q35261325-3ECD253D-2DB1-46AA-9BFD-9F04C098359B Q35285768-5F895AE6-068D-4958-81A0-ACB80A5CB5B9 Q35506253-0D9602EA-9E1E-4F95-AAC0-B4893DA1F058 Q35599319-EAE281EA-D819-4D54-8E51-31D9E1768D22 Q35651085-7C994655-6094-431F-92AA-ED11E56997C9 Q35653264-913B320A-11B8-44D8-854F-B1EE90295F47 Q35717021-2E57BDE6-55B0-4706-A2BE-E3C263E8D76F Q36023115-9B9D1ABA-7128-46F2-BBC1-E1A059C6990F Q36220624-4B9EBB54-A7FF-41E5-9F39-6F941896F43C Q36664201-0119CEFE-804B-4E18-89BE-6895C0A433DA Q36757131-D1CE5BDC-47D0-4BDE-81CD-0C74DE9DC317 Q36925337-9A3CD5B2-BA71-4A3F-AA90-5F514C0DADE4 Q37132233-9EB4F49D-26BA-4AB4-917D-3D6618082C60 Q37945193-104A36B3-2B0C-4349-9CA4-D7BC9747F66D Q38614156-EEACDC0C-04B7-4A3A-B413-58996D432797 Q39308911-351F7817-1A46-400A-AE63-7DF6FD03C62F Q39532576-13D55307-81F1-43B6-A6A5-BA1ADD865DA3 Q39616158-541479B6-C4FD-4A40-8038-A994E7C53CAC Q39868041-127E99ED-2AE6-4968-B948-72CEC294486B Q40087457-F9C44F90-C344-4FFE-ACC1-99010636B82A Q42254679-D6C3B6DA-88FE-481D-B605-02F7900B8892 Q42324174-F6C2E5EE-74F9-4771-AC30-FB5925A2A85A Q42709652-5EC3CB37-0E75-4729-832B-A279DBBE7ADB Q45866594-ACD96300-00DB-4146-A541-7F2A53493918 Q45869559-94B2199B-CB0A-4E23-B159-2E3CA0006170 Q49787495-AE1B765B-AE88-42EE-A806-186587781D36

P2860

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

http://www.wikidata.org/entity/Q33388660

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prolonged systemic circulation ...... c and refractory solid tumors.

@ast

Prolonged systemic circulation ...... c and refractory solid tumors.

@en

type

label

Prolonged systemic circulation ...... c and refractory solid tumors.

@ast

Prolonged systemic circulation ...... c and refractory solid tumors.

@en

prefLabel

Prolonged systemic circulation ...... c and refractory solid tumors.

@ast

Prolonged systemic circulation ...... c and refractory solid tumors.

@en

P1433

Q33388660-85E15CA9-5B8D-45CC-93C0-1241340961B3

P1476

Q33388660-55013DC1-341D-4F54-AC3F-457BA64C26E7

P2093

Q33388660-0DEEF0ED-6903-4336-8640-3DE642DC120F

Q33388660-2261F817-F8B5-423D-B004-1EC24BC5C1F9

Q33388660-27502C75-AAF4-4651-A16F-1D53ADCC2F70

Q33388660-2AD23421-C09A-4C6C-9A59-64347D2ABE95

Q33388660-322841FE-8B07-481D-83CB-571D73DE4FEC

Q33388660-3A7CC7BD-0E2B-4C98-9EBE-85A5D95543F7

Q33388660-666959F6-0DCB-4C98-8427-AF79A6482218

Q33388660-6F0978E9-48A5-4A36-A5DA-3D6890F61999

Q33388660-7C231461-9242-4814-A2E3-5F040A08F3BE

Q33388660-7EE13036-8BE9-4663-9FDD-A285EE346F03

P2888

Q33388660-0AFFA7E9-305C-4E62-95C1-5FC632DE5D1B

P304

Q33388660-F629E12B-5EB2-440F-92BC-0E2CCA54845C

P31

Q33388660-D0EB5B35-BFAE-4768-9BEC-33E27E687B80

P356

Q33388660-F0263AE3-4784-4E5D-83BE-FB77070B386C

P433

Q33388660-B6A79CDA-47C2-42D5-A7EC-A4202C0338EF

P478

Q33388660-EEE5B6F0-4998-4B0B-8394-07AB1E5DF0D3

P50

Q33388660-873C6918-18CB-4C4D-8D8A-B6F30A033C1D

Q33388660-D62C757A-1392-431F-A097-37D3F9482CF8

P577

Q33388660-92BF715C-510A-4DD1-8FAB-AF85B8272FE4

P5875

Q33388660-9F776B35-BB56-46B6-983C-63AB81B61016

P6179

Q33388660-80833EDD-8A04-4EF2-827A-B4D63186C8E2

P698

Q33388660-05994F61-DDC1-4792-BC72-2615E279AD82

P921

Q33388660-7B2EE94B-E14C-4E05-826B-08F2A9326232

Q33388660-AE249872-4319-4628-A835-2204424E4909

P356

P1433

P1476

Prolonged systemic circulation ...... c and refractory solid tumors.

@en

P2093

A Helminen

http://www.w3.org/2001/XMLSchema#string

A Hemminki

http://www.w3.org/2001/XMLSchema#string

A Kanerva

http://www.w3.org/2001/XMLSchema#string

A Karioja-Kallio

http://www.w3.org/2001/XMLSchema#string

A Ristimäki

http://www.w3.org/2001/XMLSchema#string

C Ribacka

http://www.w3.org/2001/XMLSchema#string

E Haavisto

http://www.w3.org/2001/XMLSchema#string

E Karli

http://www.w3.org/2001/XMLSchema#string

G Bauerschmitz

http://www.w3.org/2001/XMLSchema#string

K Guse

http://www.w3.org/2001/XMLSchema#string

P2888

P304

892-904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GT.2010.17

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Vincenzo Cerullo

P577

2010-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42255556

http://www.w3.org/2001/XMLSchema#string

P6179

1021553080

http://www.w3.org/2001/XMLSchema#string

P698

20237509

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus